EU Internal Policy

EU medicine agency in new threat to punish Britain by slapping levies on UK drugs

THE European Medicines Agency (EMA) has threatening to slap import levies on British-made medicines being sold within the EU and add bureaucratic red tape once Brexit is completed.

The European Commission and the European Medicines Agency issued a joint four-page document that set out how it saw operations working over Brexit.The document stated that UK companies would have to set up some operations related to drug safety and approval with the EU to ensure their products comply with EU requirements.It added that authorisation to sell a drug within the European Economic Area would have to be given by at least one member state’s regulatory body.

EMA Canary Wharf, LondonGetty/AFP                  The EU could impose red tape and levies on British medicines imported into the EU

The Brussels paper illustrated the amount of disruption that could be caused to UK companies.The Association of the British Pharmaceutical Industry (ABPI) said that setting up any such operation could take several years, which added pressure on the Government to negotiate a deal, or even a transitory agreement, before the expected date of the UK’s exit from the bloc.ABPI Executive Director Dr Virginia Acha said: “The UK and European life sciences industry has regularly highlighted the importance of resolving the regulatory, supply and trading arrangements for medicines after the UK leaves the European Union, and the complexity involved in this process.


“However, the Brexit negotiations between the UK and EU have yet to start and their ultimate outcome is unknown, so it seems premature to advise companies to prepare only for an outcome where the UK is isolated from the European system.

“This Q&A refers to some of the many potential challenges ahead and further discussion and guidance will be needed as we seek to ensure that medicines continue to be developed and delivered to patients across Europe.”

Dr Acha added: “In an outcome where the UK is isolated from the European system for medicines regulation, companies in the UK will have to consider all options for the location of sites, systems and staff, to meet the requirements of the EMA and other regulatory bodies.”Currently the EMA is based in Canary Wharf, east London, which is responsible for authorising medicines for sale across the EU.However the European Union has stated that the body cannot remain in Britain once it has withdrawn from the bloc.

With that in mind the paper states that should the EU and UK not reach an agreement before the Brexit deadline then both substances used in the manufacture of the medicines, as well as the final product, would be considered imports and so impose a levy.

Jean-Claude JunckerAFP          European Commission President Jean-Claude Juncker

The move could have a big impact on Britain’s lucrative generic industry which would be hit by such a tax.The British Generic Manufacturers Association estimates that its medicines have saved the National Health Service about £13billion a year.Health Secretary Jeremy Hunt told a Commons committee in January that the EMA is likely to move its office from London to elsewhere in Europe.

MPs were told the UK would seek a “relationship” with the EMA after Brexit, but the Health Secretary did not say if the Government would seek continued membership.

Leave a Reply

Help put the World to rights and leave a Comment

Notify of
Jane Davies
Jane Davies

Surely the only ones to suffer are the sick?

Time to stop this crazy game with Juncker and his band of crooks, just walk away and then take pleasure in watching the whole corrupt organization implode.

Powered by: Wordpress
%d bloggers like this: